News shortcuts: From the Courts | Top Headlines | VAT (Value Added Tax) | Placements & Empanelment | Various Acts & Rules | Latest Circulars | New Forms | Forex | Auditing | Direct Tax | Customs and Excise | Professional Updates | Corporate Law | Markets | Students | General | Mergers and Acquisitions | Continuing Prof. Edu. | Budget Extravaganza | Transfer Pricing | GST - Goods and Services Tax
Mergers and Acquisitions »
 Deals of the day-Mergers and acquisitions February 4, 2020
 The mergers and acquisitions perspective
 Deals of the day-Mergers and acquisitions January 6, 2020
 Mergers and Acquisitions in Vietnam – Latest Issue of Vietnam Briefing Magazine
 Deals of the day-Mergers and acquisitions December 17, 2019
 Deals of the day-Mergers and acquisitions December 11, 2019
 Deals of the day-Mergers and acquisitions December 6, 2019
 Mergers and acquisitions up in 2019 but deal sizes are shrinking
 Global economic uncertainties dampen India's M&A activity in August
  M&A deals more than halve to $41.6 bn in January-June
 India Lithium-ion Battery Market Key Developments, Mergers and Acquisitions, Market Players, Forecast Analysis

Deals of the day-Mergers and acquisitions July 30
August, 02nd 2019

As part of the Upjohn-Mylan deal, the Indian unit of US drug major Pfizer announced on July 30 that it will be transferring six brands to the combined entity.

The merger of Pfizer’s off-patent branded drugs division Upjohn with generic drugmaker Mylan may have only a minor impact on the way the two companies operate in India, sources told Moneycontrol.

As part of the Upjohn-Mylan deal, the Indian unit of US drug major Pfizer announced on July 30 that it will be transferring six brands to the combined entity.

The rest of the Pfizer’s India business will remain as it is, said the company’s spokesperson to Moneycontrol.

The six brands include anti-neuropathic pain drug Lyrica, anti-hypertension drug Amlogard, antidepressant Daxid, anti-seizure Dilantin, Viagra to treat erectile dysfunction and anti-fungal Fumycin.

Pramod Mittal's arrest in Bosnia part of Global Ispat Koksna hostile takeover plan, alleges his firm
Vistara to launch Mumbai-Dubai flight services from August 21
Auto industry slowdown: Manufacturers pin hopes on a GST rate cut from govt
The sales of the brands are not disclosed. But analysts say they aren’t huge contributors for Pfizer’s revenue, as all of them face competition from Indian generic brands.

Pfizer is listed on Indian stock exchanges.

The company has annual sales of Rs 2,030 crore, with a portfolio of over 150 products across 15 therapeutic areas.

Pfizer in India sells branded generics (off-patented drugs), vaccines and consumer health products, and known for brands such as Prevnar, Gelusil, Minipress-XL, Corex, Magnex, Becosules, Mucaine, and Dolonex.

The company had earlier decided to merge its consumer health business with GSK.

Mylan operations

On the other hand, there isn’t any indication so far on the restructuring of any operations in India by Mylan.

Mylan has a huge manufacturing and R&D footprint in India feeding the global supply chain of Mylan.

Mylan built its manufacturing base in India through acquisitions of Hyderabad-based Matrix Labs in 2007 and Bengaluru-based injectable manufacturing operation of Strides.

The company's global R&D centre, that’s responsible for most of its abbreviated new drug application (ANDA) filings in the US is based out of Hyderabad.

Mylan has 25 facilities located in India that include nine API facilities, eight oral solid dosage (OSD) plants and eight injectables units based in Hyderabad, Visakhapatnam, Bengaluru and Ahmedabad that make active pharmaceutical ingredients (APIs), formulations including injectable formulations.

Mylan employs about 15,000 people in India.

The company is also a part of India's formulation business. It sells hepatitis-C, antiretrovirals and biosimilar drugs in India. The business size is, however, small.

Mylan's partnerships

Mylan's partnerships with Biocon for developing and commercializing biosimilars will also remain intact.

“Certainly nothing changes for us in terms of our business with Mylan because this actually offers us a much larger opportunity. In yesterday’s presentation, you can see that the combined entity actually is going to rely on a pretty decent contribution from biosimilars and they have mentioned the biosimilar that we are currently commercialising with Mylan, which is Ogivri that is our biosimilar trastuzumab, fulphila, biosimilar pegfilgrastim and semglee glargine and the biosimilar adalimumab,” Mazumdar-Shaw told CNBC-TV18 on July 30.

Natco too has a partnership with Mylan for multiple sclerosis drug glatiramer acetate injection or generic Copaxone in the US market. Pfizer supplies glatiramer acetate injection to Momenta-Sandoz and Synthon. It needs to be seen whether the deal will have any impact.

M&A opportunities

But a top executive of an Indian generic company said the deal could open-up potential acquisition opportunities for Indian companies looking to expand their portfolios or strengthen their presence in the US, Europe, China and other emerging opportunities, as the drug makers may have to divest brands that overlap in various markets to get approval of antitrust regulators.

Home | About Us | Terms and Conditions | Contact Us
Copyright 2020 CAinINDIA All Right Reserved.
Designed and Developed by Ritz Consulting